Citi has identified an attractive risk-reward scenario for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) in advance of headline data from a critical trial of its cardiac treatment Wainua, with results anticipated during
Pharmaceutical
192Articles
The recent remarks made by Lord Vallance of Balham at The Times Life Sciences Summit have stirred considerable discussion within the United Kingdom’s commercial and scientific communities. As the former
The venerable British pharmacy chain Boots is embarking on a new chapter as it prepares for a potential initial public offering (IPO) that could value the company at £7 billion.
hVIVO PLC, the AIM-listed specialist in human challenge trials, has secured a contract with a new European biotechnology client for an influenza challenge study, marking the third such agreement announced
AstraZeneca has committed to reactivating a £200 million investment at its Cambridge headquarters, alongside a new £100 million funding initiative for its site in Macclesfield. This decision comes in the
In a significant move for the burgeoning psychedelic industry, President Trump signed an executive order aimed at expediting the review of psychedelic therapies, as well as increasing federal research funding.
HM Revenue and Customs has announced a pause in enforcing VAT charges on medicines supplied under early access schemes, amid rising concerns from the pharmaceutical industry. The decision comes after
NHS patients in the United Kingdom are being warned of imminent prescription shortages if a diplomatic resolution is not reached between the United States and Iran. Drug manufacturers have raised
GSK has announced promising results from early trials of a new gynaecological cancer drug, which it aims to fast-track for market release in the coming years. The pharmaceutical giant is
ImmunityBio has announced the implementation of comprehensive regulatory compliance measures following a warning letter from the Food and Drug Administration regarding promotional claims for Anktiva, its bladder cancer treatment. The
A subculture once confined to the margins of competitive bodybuilding has migrated into the mainstream wellness economy at remarkable speed. The proliferation of unregulated peptide compounds, sold openly online and
Poolbeg Pharma PLC has announced the grant of its first national patent covering the POLB-001 programme, which addresses cytokine release syndrome induced by cancer immunotherapy. The development represents a significant
<p>The National Institute for Health and Care Excellence (NICE) has recommended that semaglutide, the active compound marketed under the brand names Wegovy and Ozempic, be prescribed to more than one
The successful commercial deployment of a newly approved grass pollen immunotherapy is expected to establish a foundation for long-term profitability at Allergy Therapeutics PLC, according to broker analysis from Cavendish.
Shares in Poolbeg Pharma PLC climbed as much as 10% during Tuesday morning trading following confirmation that the company has secured its first national patent grant for POLB 001, its
Bayer has halted the acceptance of new patients into its early access scheme, amidst an ongoing dispute with HMRC regarding tax liabilities on free-of-charge medicines. This decision has raised concerns
